Selective Estrogen Receptor Modulators
"Selective Estrogen Receptor Modulators" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)
| Descriptor ID |
D020845
|
| MeSH Number(s) |
D06.347.360.827 D27.505.696.399.450.360.827
|
| Concept/Terms |
Selective Estrogen Receptor Modulators- Selective Estrogen Receptor Modulators
- SERMs
- Estrogen Receptor Modulators, Selective
- Selective Estrogen Receptor Modulator
- SERM
- Estrogen Receptor Modulator, Selective
|
Below are MeSH descriptors whose meaning is more general than "Selective Estrogen Receptor Modulators".
Below are MeSH descriptors whose meaning is more specific than "Selective Estrogen Receptor Modulators".
This graph shows the total number of publications written about "Selective Estrogen Receptor Modulators" by people in this website by year, and whether "Selective Estrogen Receptor Modulators" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2013 | 2 | 1 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Selective Estrogen Receptor Modulators" by people in Profiles.
-
Piccolella M, Crippa V, Cristofani R, Rusmini P, Galbiati M, Cicardi ME, Meroni M, Ferri N, Morelli FF, Carra S, Messi E, Poletti A. The small heat shock protein B8 (HSPB8) modulates proliferation and migration of breast cancer cells. Oncotarget. 2017 Feb 07; 8(6):10400-10415.
-
Archer DF, Freeman EW, Komm BS, Ryan KA, Yu CR, Mirkin S, Pinkerton JV. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials. J Womens Health (Larchmt). 2016 11; 25(11):1102-1111.
-
Pinkerton JV, Pickar JH, Ryan KA, Yu CR, Mirkin S, Komm BS. Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials. Menopause. 2016 06; 23(6):611-20.
-
Stevenson JC, Chines A, Pan K, Ryan KA, Mirkin S. A Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials. J Clin Endocrinol Metab. 2015 Jun; 100(6):2329-38.
-
Abraham L, Pinkerton JV, Messig M, Ryan KA, Komm BS, Mirkin S. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene. Maturitas. 2014 Jul; 78(3):212-8.
-
de la Cruz MS, Sarfaty M, Wender RC. An update on breast cancer screening and prevention. Prim Care. 2014 Jun; 41(2):283-306.
-
Mirkin S, Ryan KA, Chandran AB, Komm BS. Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms. Maturitas. 2014 Jan; 77(1):24-31.
-
Brailoiu GC, Benamar K, Arterburn JB, Gao E, Rabinowitz JE, Koch WJ, Brailoiu E. Aldosterone increases cardiac vagal tone via G protein-coupled oestrogen receptor activation. J Physiol. 2013 Sep 01; 591(17):4223-35.
-
Pinkerton JV, Harvey JA, Pan K, Thompson JR, Ryan KA, Chines AA, Mirkin S. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol. 2013 May; 121(5):959-968.
-
Balaburski GM, Dardes RC, Johnson M, Haddad B, Zhu F, Ross EA, Sengupta S, Klein-Szanto A, Liu H, Lee ES, Kim H, Jordan VC. Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance. Int J Oncol. 2010 Aug; 37(2):387-98.